Medicare Coverage of Items and Services in FDA Investigational Device Exemption Clinical Studies--Revision of Medicare Coverage

ICR 201312-0938-010

OMB: 0938-1250

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2014-08-20
ICR Details
0938-1250 201312-0938-010
Historical Active
HHS/CMS 21117
Medicare Coverage of Items and Services in FDA Investigational Device Exemption Clinical Studies--Revision of Medicare Coverage
New collection (Request for a new OMB Control Number)   No
Regular
Approved with change 08/26/2014
Retrieve Notice of Action (NOA) 12/11/2013
OMB is approving this information collection request for a period of three years during which time CMS will request approval to extend or revise the collection if the Agency seeks to continue the information collection activity beyond the period approved under this action.
  Inventory as of this Action Requested Previously Approved
08/31/2017 36 Months From Approved
240 0 0
480 0 0
0 0 0

Section 1862(m) of the Act (established by section 731(b) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108-173, enacted on December 8, 2003)) allows for payment of the routine costs of care furnished to Medicare beneficiaries in a Category A investigational device exemption (IDE) trial and authorizes the Secretary to establish criteria to ensure that Category A IDE trials conform to appropriate scientific and ethical standards. By providing Medicare coverage of routine costs in Category A trials, the Congress removed a financial barrier that may have discouraged beneficiaries from participating in these trials. It also gives Medicare beneficiaries the opportunity to have earlier access to new medical devices. Based on our rulemaking authority in section 1871 of the Act, we are applying the same Medicare coverage requirements and scientific and ethical standards to Medicare coverage related to Category B IDE studies/trials that would be applicable to Category A IDE studies/trials. CMS (or its designated entity) must review the following to determine if the Medicare coverage IDE study criteria in ?405.212 are met for purposes of coverage of items and services described in paragraphs (a) and (b) of this section: (1) FDA IDE approval letter. (2) IDE study protocol. (3) IRB approval letter. (4) National Clinical Trials (NCT) number. (5) Supporting materials, as needed.

US Code: 42 USC 1861 Name of Law: Social Security Act: Part E--Miscellaneous Provisions DEFINITIONS OF SERVICES, INSTITUTIONS, ETC
   US Code: 42 USC 205(a) Name of Law: Social Security Act: EVIDENCE, PROCEDURE, AND CERTIFICATION FOR PAYMENT
   US Code: 42 USC 1102 Name of Law: Social Security Act: RULES AND REGULATIONS
  
US Code: 42 USC 1861 Name of Law: Social Security Act
US Code: 42 USC 205(a) Name of Law: Social Security Act
US Code: 42 USC 1102 Name of Law: Social Security Act

0938-AR56 Final or interim final rulemaking 78 FR 74683 12/10/2013

  78 FR 43282 07/19/2013
78 FR 74683 12/10/2013
No

1
IC Title Form No. Form Name
Medical Services Coverage Decisions That Relate to Health Care Technology (42 CFR 405.211)

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 240 0 240 0 0 0
Annual Time Burden (Hours) 480 0 480 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
Not applicable. This is a new collection.

$0
No
No
No
No
No
Uncollected
Mitch Bryman 410 786-5258 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
12/11/2013


© 2024 OMB.report | Privacy Policy